 Home > Active Ingredient News > Infection > ZYESAMI treats COVID-19 respiratory failure, phase IIb/III clinical trial achieves positive results

ZYESAMI treats COVID-19 respiratory failure, phase IIb/III clinical trial achieves positive results

 Last Update: 2021-04-13
 Source: Internet
 Author: User

Tags

blood parasites

blood cooked chicken

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The pharmaceutical company NeuroRx announced today that the Phase IIb/III clinical trial under the FDA Fast Track designation has completed 60-day top-line data analysis.

The FDA COVID.

Vasoactive intestinal polypeptide (VIP) was first discovered in 1970 by the late Dr.

Most importantly, VIP specifically binds to type II alveolar cells (ATII).

infection

Original source:

href="" target="_blank" rel="noopener">leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Sodium cloxacillin

CAS No.: 642-78-4

$3/KG EXW

Isoniazid 54-85-3

CAS No.: 54-85-3

Pharmacy Grade

$2-2.5/KG FOB

Andrographolide

CAS No.: 5508-58-7

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.